What’s Next for mRNA? From COVID to Cancer & Beyond
Summary: Interest in mRNA as a therapeutic modality has exploded due to the approval of mRNA-based COVID-19 vaccines. Now that the pharma industry and regulators have significant data on safety and efficacy of mRNA vaccines, many new companies are entering the mRNA market, and existing mRNA players are expanding their pipelines. While there is interest to leverage mRNA for other vaccines (for example against influenza), these companies are also looking beyond infectious disease to potentially develop therapies for a wide variety of indications. During this Q&A, we discuss the challenges of mRNA development and manufacturing, potential solutions and where the industry may go next with mRNA therapies.